These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 19336954)

  • 1. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of azithromycin as the empiric therapy in children with community-acquired pneumonia who were isolated macrolide resistant Streptococcus pneumoniae from nasopharynx].
    Nariai A; Okitsu N; Inoue M
    Kansenshogaku Zasshi; 2004 Jun; 78(6):490-5. PubMed ID: 15287476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Azithromycin and bronchopulmonary infections].
    Leophonte P
    Pathol Biol (Paris); 1995 Jun; 43(6):534-41. PubMed ID: 8539078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
    Yayan J
    Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study.
    Meyer Sauteur PM; Seiler M; Tilen R; Osuna E; von Wantoch M; Sidorov S; Aebi C; Agyeman P; Barbey F; Bielicki JA; Coulon L; Deubzer B; Donas A; Heininger U; Keitel K; Köhler H; Kottanattu L; Lauener R; Niederer-Loher A; Posfay-Barbe KM; Tomaske M; Wagner N; Zimmermann P; Zucol F; von Felten S; Berger C
    Trials; 2024 Oct; 25(1):655. PubMed ID: 39363201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].
    Yin YD; Cao B; Wang H; Wang RT; Liu YM; Gao Y; Qu JX; Han GJ; Liu YN
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):954-8. PubMed ID: 24503430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.
    Isozumi R; Ito Y; Ishida T; Osawa M; Hirai T; Ito I; Maniwa K; Hayashi M; Kagioka H; Hirabayashi M; Onari K; Tomioka H; Tomii K; Gohma I; Imai S; Takakura S; Iinuma Y; Ichiyama S; Mishima M;
    J Clin Microbiol; 2007 May; 45(5):1440-6. PubMed ID: 17344362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].
    Bao F; Qu JX; Liu ZJ; Qin XG; Cao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):756-61. PubMed ID: 24433804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
    Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
    Fujita J; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Tanigawara Y; Cash HL; Kohno S
    J Infect Chemother; 2013 Jun; 19(3):472-9. PubMed ID: 23179958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
    Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
    Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.